These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21779410)

  • 1. Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models.
    Persson J; Beyer I; Yumul R; Li Z; Kiem HP; Roffler S; Lieber A
    PLoS One; 2011; 6(7):e22303. PubMed ID: 21779410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
    Hebb JPO; Mosley AR; Vences-Catalán F; Rajasekaran N; Rosén A; Ellmark P; Felsher DW
    Cancer Immunol Immunother; 2018 Jan; 67(1):47-60. PubMed ID: 28905118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice.
    Ahern E; Harjunpää H; Barkauskas D; Allen S; Takeda K; Yagita H; Wyld D; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2017 Oct; 23(19):5789-5801. PubMed ID: 28634284
    [No Abstract]   [Full Text] [Related]  

  • 4. Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse models.
    Liu Y; Tuve S; Persson J; Beyer I; Yumul R; Li ZY; Tragoolpua K; Hellström KE; Roffler S; Lieber A
    Cancer Gene Ther; 2011 Jun; 18(6):407-18. PubMed ID: 21394107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic
    Li C; Course MM; McNeish IA; Drescher CW; Valdmanis PN; Lieber A
    Cancer Res; 2020 Feb; 80(3):549-560. PubMed ID: 31727629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
    Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
    Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of immunotherapeutic effects of HPV16E7 on cervical cancer by fusion with CTLA4 extracellular region.
    Zheng Y; Zhang Y; Ma Y; Wan J; Shi C; Huang L
    J Microbiol; 2008 Dec; 46(6):728-36. PubMed ID: 19107404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
    Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
    Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.
    Fong L; Kwek SS; O'Brien S; Kavanagh B; McNeel DG; Weinberg V; Lin AM; Rosenberg J; Ryan CJ; Rini BI; Small EJ
    Cancer Res; 2009 Jan; 69(2):609-15. PubMed ID: 19147575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors.
    Agarwala SS; Ribas A
    J Immunother; 2010; 33(6):557-69. PubMed ID: 20551840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
    Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
    Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches.
    Chang HW; Frey G; Liu H; Xing C; Steinman L; Boyle WJ; Short JM
    Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33627407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4).
    Zhao Y; Wei Z; Yang H; Li X; Wang Q; Wang L; Li S
    Biomed Pharmacother; 2017 Jun; 90():147-152. PubMed ID: 28351777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
    Thompson RH; Allison JP; Kwon ED
    Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model.
    Yshii LM; Gebauer CM; Pignolet B; Mauré E; Quériault C; Pierau M; Saito H; Suzuki N; Brunner-Weinzierl M; Bauer J; Liblau R
    Brain; 2016 Nov; 139(11):2923-2934. PubMed ID: 27604307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade.
    Yamazaki T; Pitt JM; Vétizou M; Marabelle A; Flores C; Rekdal Ø; Kroemer G; Zitvogel L
    Cell Death Differ; 2016 Jun; 23(6):1004-15. PubMed ID: 27082453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors.
    Gao Y; Whitaker-Dowling P; Griffin JA; Barmada MA; Bergman I
    Cancer Gene Ther; 2009 Jan; 16(1):44-52. PubMed ID: 18654610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
    Pai CS; Simons DM; Lu X; Evans M; Wei J; Wang YH; Chen M; Huang J; Park C; Chang A; Wang J; Westmoreland S; Beam C; Banach D; Bowley D; Dong F; Seagal J; Ritacco W; Richardson PL; Mitra S; Lynch G; Bousquet P; Mankovich J; Kingsbury G; Fong L
    J Clin Invest; 2019 Jan; 129(1):349-363. PubMed ID: 30530991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies.
    Korman A; Yellin M; Keler T
    Curr Opin Investig Drugs; 2005 Jun; 6(6):582-91. PubMed ID: 15988909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
    Vijayakumar G; McCroskery S; Palese P
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.